Turnaround times for molecular testing of pediatric viral cerebrospinal fluid samples in United Kingdom laboratories.
World J Clin Pediatr
; 11(3): 289-294, 2022 May 09.
Article
in English
| MEDLINE | ID: covidwho-1876046
ABSTRACT
BACKGROUND:
Rapid molecular testing has revolutionized the management of suspected viral meningitis and encephalitis by providing an etiological diagnosis in < 90 min with potential to improve outcomes and shorten inpatient stays. However, use of molecular assays can vary widely.AIM:
To evaluate current practice for molecular testing of pediatric cerebrospinal fluid (CSF) samples across the United Kingdom using a structured questionnaire.METHODS:
A structured telephone questionnaire survey was conducted between July and August 2020. Data was collected on the availability of viral CSF nucleic acid amplification testing (NAAT), criteria used for testing and turnaround times including the impact of the coronavirus disease 2019 pandemic.RESULTS:
Of 196/212 (92%) microbiology laboratories responded; 63/196 (32%) were excluded from final analysis as they had no on-site microbiology laboratory and outsourced their samples. Of 133 Laboratories included in the study, 47/133 (35%) had onsite facilities for viral CSF NAAT. Hospitals currently undertaking onsite NAAT (n = 47) had much faster turnaround times with 39 centers (83%) providing results in ≤ 24 h as compared to those referring samples to neighboring laboratories (5/86; 6%).CONCLUSION:
Onsite/near-patient rapid NAAT (including polymerase chain reaction) is recommended wherever possible to optimize patient management in the acute setting.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Etiology study
/
Experimental Studies
/
Observational study
/
Qualitative research
Language:
English
Journal:
World J Clin Pediatr
Year:
2022
Document Type:
Article
Affiliation country:
Wjcp.v11.i3.289
Similar
MEDLINE
...
LILACS
LIS